Concepts (294)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Papillomaviridae | 4 | 2019 | 404 | 0.85 | Why? |
| Condylomata Acuminata | 1 | 2020 | 62 | 0.83 | Why? |
| Papillomavirus Infections | 5 | 2019 | 861 | 0.80 | Why? |
| Toothbrushing | 1 | 2019 | 40 | 0.77 | Why? |
| Vanadium Compounds | 4 | 2018 | 6 | 0.76 | Why? |
| Dermatitis, Irritant | 1 | 2020 | 99 | 0.76 | Why? |
| Emollients | 1 | 2018 | 108 | 0.72 | Why? |
| Dermatitis, Allergic Contact | 7 | 2018 | 185 | 0.72 | Why? |
| Uridine Monophosphate | 1 | 2017 | 41 | 0.71 | Why? |
| Work Capacity Evaluation | 1 | 2017 | 33 | 0.70 | Why? |
| Laser Therapy | 1 | 2020 | 158 | 0.70 | Why? |
| Lymphogranuloma Venereum | 1 | 2017 | 23 | 0.69 | Why? |
| Fluorenes | 1 | 2017 | 101 | 0.66 | Why? |
| Sarcoma, Kaposi | 1 | 2017 | 97 | 0.64 | Why? |
| Career Mobility | 1 | 2017 | 224 | 0.58 | Why? |
| Asbestos | 4 | 2018 | 45 | 0.56 | Why? |
| Benzimidazoles | 1 | 2017 | 275 | 0.56 | Why? |
| Dermatitis, Atopic | 3 | 2021 | 714 | 0.55 | Why? |
| Mouthwashes | 1 | 2019 | 432 | 0.54 | Why? |
| HIV | 2 | 2020 | 1116 | 0.53 | Why? |
| Mouth | 1 | 2019 | 622 | 0.53 | Why? |
| Mesothelioma | 3 | 2018 | 76 | 0.49 | Why? |
| Dermatologic Agents | 1 | 2018 | 489 | 0.48 | Why? |
| Chilblains | 1 | 2021 | 1156 | 0.41 | Why? |
| Hand Disinfection | 1 | 2020 | 1671 | 0.41 | Why? |
| Hair Dyes | 2 | 2018 | 8 | 0.39 | Why? |
| Phenylenediamines | 2 | 2018 | 19 | 0.38 | Why? |
| Chemokine CXCL11 | 2 | 2018 | 48 | 0.37 | Why? |
| Hepatitis C, Chronic | 1 | 2017 | 973 | 0.36 | Why? |
| Chemokine CXCL9 | 2 | 2018 | 154 | 0.34 | Why? |
| Consumer Product Safety | 1 | 2007 | 57 | 0.34 | Why? |
| Homosexuality, Male | 4 | 2018 | 1158 | 0.30 | Why? |
| Metals | 1 | 2007 | 182 | 0.30 | Why? |
| Remote Consultation | 1 | 2020 | 2396 | 0.30 | Why? |
| HIV Infections | 7 | 2020 | 11620 | 0.29 | Why? |
| Quality of Life | 5 | 2020 | 9820 | 0.28 | Why? |
| Stress Disorders, Post-Traumatic | 1 | 2021 | 2963 | 0.27 | Why? |
| Chemokine CXCL10 | 2 | 2018 | 565 | 0.26 | Why? |
| Rome | 3 | 2020 | 497 | 0.24 | Why? |
| Adaptation, Psychological | 1 | 2021 | 4996 | 0.24 | Why? |
| Health Personnel | 4 | 2021 | 29646 | 0.24 | Why? |
| Occupational Diseases | 4 | 2021 | 2787 | 0.24 | Why? |
| Occupational Health | 2 | 2018 | 3965 | 0.23 | Why? |
| Interleukin-8 | 2 | 2018 | 964 | 0.23 | Why? |
| Urticaria | 2 | 2017 | 472 | 0.22 | Why? |
| Administration, Cutaneous | 2 | 2018 | 229 | 0.22 | Why? |
| Italy | 21 | 2021 | 38444 | 0.21 | Why? |
| Cell Proliferation | 5 | 2019 | 1973 | 0.21 | Why? |
| Brain Neoplasms | 2 | 2017 | 669 | 0.21 | Why? |
| Patch Tests | 6 | 2018 | 114 | 0.21 | Why? |
| Facial Neoplasms | 1 | 2020 | 51 | 0.20 | Why? |
| Paraffin | 1 | 2018 | 7 | 0.20 | Why? |
| Cytochrome P-450 CYP2E1 | 1 | 2018 | 15 | 0.19 | Why? |
| Epoxy Compounds | 1 | 2018 | 21 | 0.19 | Why? |
| Thyroid Epithelial Cells | 1 | 2018 | 3 | 0.19 | Why? |
| HIV Integrase | 1 | 2019 | 67 | 0.19 | Why? |
| Acrylamide | 1 | 2018 | 24 | 0.19 | Why? |
| Skin Cream | 1 | 2018 | 66 | 0.19 | Why? |
| Asbestosis | 1 | 2018 | 8 | 0.19 | Why? |
| Hand-Foot Syndrome | 1 | 2018 | 15 | 0.19 | Why? |
| Glycerol | 1 | 2018 | 52 | 0.18 | Why? |
| Anus Diseases | 1 | 2018 | 55 | 0.18 | Why? |
| Genomic Instability | 1 | 2018 | 80 | 0.18 | Why? |
| Pleural Neoplasms | 1 | 2018 | 71 | 0.17 | Why? |
| Genes, ras | 1 | 1997 | 8 | 0.17 | Why? |
| Purine Nucleosides | 1 | 2017 | 22 | 0.17 | Why? |
| Dermatologists | 2 | 2020 | 435 | 0.17 | Why? |
| Deoxyguanosine | 1 | 2017 | 19 | 0.17 | Why? |
| DNA Adducts | 1 | 2017 | 10 | 0.17 | Why? |
| Oropharyngeal Neoplasms | 1 | 2019 | 138 | 0.17 | Why? |
| Facial Dermatoses | 1 | 2021 | 222 | 0.17 | Why? |
| Cytodiagnosis | 1 | 2018 | 104 | 0.17 | Why? |
| Air Pollutants, Occupational | 1 | 2018 | 108 | 0.17 | Why? |
| Fibroblasts | 2 | 2018 | 839 | 0.16 | Why? |
| Genetic Techniques | 1 | 1997 | 79 | 0.16 | Why? |
| Occupational Exposure | 4 | 2020 | 4742 | 0.16 | Why? |
| HIV Envelope Protein gp120 | 1 | 2019 | 267 | 0.16 | Why? |
| Anus Neoplasms | 1 | 2018 | 123 | 0.16 | Why? |
| Histamine Antagonists | 1 | 2017 | 203 | 0.16 | Why? |
| Neisseria gonorrhoeae | 1 | 2017 | 142 | 0.16 | Why? |
| Dermatitis, Occupational | 1 | 2021 | 310 | 0.15 | Why? |
| Chlamydia trachomatis | 1 | 2017 | 172 | 0.15 | Why? |
| Syphilis | 1 | 2020 | 318 | 0.15 | Why? |
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 343 | 0.15 | Why? |
| GPI-Linked Proteins | 1 | 2017 | 317 | 0.15 | Why? |
| DNA Damage | 1 | 2018 | 285 | 0.15 | Why? |
| Hospitals, Special | 1 | 2020 | 523 | 0.15 | Why? |
| Omalizumab | 1 | 2017 | 158 | 0.15 | Why? |
| Spondylarthritis | 1 | 2018 | 174 | 0.15 | Why? |
| MicroRNAs | 2 | 2019 | 1787 | 0.14 | Why? |
| Anxiety | 1 | 2021 | 17311 | 0.14 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2017 | 260 | 0.14 | Why? |
| Immunoglobulin E | 1 | 2017 | 557 | 0.14 | Why? |
| Drug Resistance, Viral | 2 | 2019 | 1083 | 0.14 | Why? |
| Farmers | 1 | 2017 | 280 | 0.14 | Why? |
| Mouth Diseases | 1 | 2017 | 193 | 0.14 | Why? |
| Mental Health | 1 | 2021 | 15770 | 0.14 | Why? |
| Sexually Transmitted Diseases | 2 | 2020 | 694 | 0.13 | Why? |
| Urine | 1 | 1997 | 469 | 0.13 | Why? |
| Polymers | 1 | 2018 | 507 | 0.13 | Why? |
| Humans | 53 | 2021 | 930598 | 0.12 | Why? |
| HIV-1 | 2 | 2019 | 3365 | 0.12 | Why? |
| Thyroid Gland | 1 | 2018 | 516 | 0.12 | Why? |
| Sofosbuvir | 1 | 2017 | 518 | 0.12 | Why? |
| Male | 31 | 2021 | 367725 | 0.12 | Why? |
| Adult | 28 | 2021 | 244371 | 0.12 | Why? |
| Hospitals, Teaching | 1 | 2020 | 1609 | 0.12 | Why? |
| Mastectomy | 1 | 2017 | 536 | 0.12 | Why? |
| Immunization | 1 | 2021 | 2019 | 0.12 | Why? |
| Appointments and Schedules | 1 | 2020 | 1204 | 0.11 | Why? |
| DNA | 1 | 1997 | 778 | 0.11 | Why? |
| Female | 28 | 2021 | 380317 | 0.11 | Why? |
| Patient Preference | 1 | 2017 | 750 | 0.10 | Why? |
| Middle Aged | 26 | 2021 | 270681 | 0.10 | Why? |
| Psychometrics | 1 | 2017 | 1269 | 0.10 | Why? |
| Lung Neoplasms | 2 | 2017 | 3228 | 0.10 | Why? |
| Microscopy, Confocal | 1 | 2011 | 343 | 0.10 | Why? |
| Population Surveillance | 2 | 2018 | 4967 | 0.10 | Why? |
| Carcinoma, Squamous Cell | 1 | 2018 | 902 | 0.10 | Why? |
| Genotype | 5 | 2019 | 4697 | 0.09 | Why? |
| Apoptosis | 1 | 2019 | 2335 | 0.09 | Why? |
| DNA, Viral | 1 | 2019 | 2521 | 0.09 | Why? |
| Disease Outbreaks | 3 | 2021 | 27595 | 0.09 | Why? |
| Cell Survival | 3 | 2018 | 1581 | 0.09 | Why? |
| Peptide Fragments | 1 | 2019 | 2075 | 0.09 | Why? |
| Biomarkers, Tumor | 1 | 2017 | 1314 | 0.09 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2018 | 3607 | 0.09 | Why? |
| Military Personnel | 1 | 2017 | 1097 | 0.08 | Why? |
| Dermoscopy | 1 | 2011 | 346 | 0.08 | Why? |
| Skin Neoplasms | 1 | 2020 | 1679 | 0.08 | Why? |
| Skin Tests | 1 | 2007 | 229 | 0.08 | Why? |
| Early Detection of Cancer | 1 | 2018 | 1956 | 0.08 | Why? |
| Diabetes Complications | 1 | 2018 | 2358 | 0.08 | Why? |
| Allergens | 2 | 2011 | 728 | 0.08 | Why? |
| Gene Expression Profiling | 1 | 2017 | 3788 | 0.07 | Why? |
| Nickel | 2 | 1996 | 55 | 0.07 | Why? |
| RNA, Messenger | 1 | 2019 | 5131 | 0.07 | Why? |
| Dermatology | 1 | 2020 | 1999 | 0.07 | Why? |
| Antiviral Agents | 1 | 2017 | 41703 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2018 | 1996 | 0.07 | Why? |
| Immunotherapy | 1 | 2017 | 2421 | 0.07 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.07 | Why? |
| Cells, Cultured | 3 | 2018 | 5835 | 0.06 | Why? |
| Young Adult | 9 | 2018 | 93724 | 0.06 | Why? |
| Zinc Compounds | 3 | 1999 | 62 | 0.06 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2018 | 3550 | 0.06 | Why? |
| Skin Diseases | 1 | 2018 | 2509 | 0.06 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.06 | Why? |
| Morbidity | 2 | 2017 | 1426 | 0.05 | Why? |
| Personnel, Hospital | 1 | 2014 | 2273 | 0.05 | Why? |
| Chlorides | 2 | 1999 | 82 | 0.05 | Why? |
| Cross-Sectional Studies | 5 | 2018 | 53120 | 0.05 | Why? |
| Ointments | 2 | 2018 | 54 | 0.05 | Why? |
| Aged | 13 | 2018 | 215776 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.05 | Why? |
| Thimerosal | 1 | 1999 | 15 | 0.05 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.05 | Why? |
| Databases, Factual | 1 | 2014 | 6248 | 0.05 | Why? |
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2018 | 31 | 0.05 | Why? |
| Prevalence | 5 | 2018 | 25773 | 0.05 | Why? |
| Micronucleus Tests | 1 | 2018 | 12 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.05 | Why? |
| Breast Neoplasms | 1 | 2017 | 3633 | 0.05 | Why? |
| Adolescent | 7 | 2018 | 86841 | 0.05 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.05 | Why? |
| Irritants | 2 | 1999 | 28 | 0.05 | Why? |
| Biotransformation | 1 | 2018 | 74 | 0.05 | Why? |
| Taxoids | 1 | 2018 | 45 | 0.05 | Why? |
| Inflammation | 2 | 2018 | 13255 | 0.05 | Why? |
| Capecitabine | 1 | 2018 | 51 | 0.05 | Why? |
| Masks | 1 | 2021 | 8528 | 0.04 | Why? |
| Interferon-gamma | 2 | 2018 | 2711 | 0.04 | Why? |
| Magnesium Chloride | 1 | 1996 | 4 | 0.04 | Why? |
| HIV Reverse Transcriptase | 1 | 2017 | 104 | 0.04 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.04 | Why? |
| Manganese Compounds | 1 | 1996 | 13 | 0.04 | Why? |
| Oxazines | 1 | 2019 | 279 | 0.04 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.04 | Why? |
| Carcinogens | 1 | 1997 | 33 | 0.04 | Why? |
| Risk Factors | 4 | 2019 | 71621 | 0.04 | Why? |
| HIV Protease | 1 | 2017 | 86 | 0.04 | Why? |
| Lipid Peroxidation | 1 | 2017 | 114 | 0.04 | Why? |
| Cell Hypoxia | 1 | 2017 | 141 | 0.04 | Why? |
| Polymorphism, Restriction Fragment Length | 1 | 1997 | 116 | 0.04 | Why? |
| Pesticides | 1 | 2017 | 100 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.04 | Why? |
| Radiotherapy, Adjuvant | 1 | 2017 | 180 | 0.04 | Why? |
| Genotyping Techniques | 1 | 2019 | 360 | 0.04 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.04 | Why? |
| Mutation | 1 | 1997 | 12376 | 0.04 | Why? |
| Surveys and Questionnaires | 3 | 2020 | 43792 | 0.04 | Why? |
| Diabetes Mellitus | 1 | 2018 | 8207 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.04 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 275 | 0.04 | Why? |
| Piperazines | 1 | 2019 | 445 | 0.04 | Why? |
| Codon | 1 | 1997 | 287 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.04 | Why? |
| Pilot Projects | 1 | 2007 | 5182 | 0.04 | Why? |
| Anal Canal | 1 | 2018 | 367 | 0.04 | Why? |
| Luciferases | 1 | 2017 | 378 | 0.04 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.04 | Why? |
| Environmental Monitoring | 1 | 2007 | 3143 | 0.04 | Why? |
| Uveitis | 1 | 2018 | 233 | 0.04 | Why? |
| Stakeholder Participation | 1 | 2018 | 481 | 0.03 | Why? |
| Epidemiological Monitoring | 1 | 2007 | 3493 | 0.03 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.03 | Why? |
| European Union | 1 | 2018 | 565 | 0.03 | Why? |
| Analysis of Variance | 1 | 2017 | 950 | 0.03 | Why? |
| Severity of Illness Index | 2 | 2018 | 48226 | 0.03 | Why? |
| Gene Frequency | 1 | 2018 | 1210 | 0.03 | Why? |
| Pyridones | 1 | 2019 | 738 | 0.03 | Why? |
| Patient Care Planning | 1 | 2018 | 582 | 0.03 | Why? |
| Energy Metabolism | 1 | 2017 | 451 | 0.03 | Why? |
| Chronic Disease | 2 | 2017 | 5139 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.03 | Why? |
| Alleles | 1 | 2017 | 1557 | 0.03 | Why? |
| Population Dynamics | 1 | 2014 | 378 | 0.03 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1014 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2017 | 1136 | 0.03 | Why? |
| Cooperative Behavior | 1 | 2018 | 1216 | 0.03 | Why? |
| Educational Status | 1 | 2017 | 1451 | 0.03 | Why? |
| Interdisciplinary Communication | 1 | 2018 | 1425 | 0.03 | Why? |
| Urinary Bladder Neoplasms | 1 | 1997 | 614 | 0.03 | Why? |
| Self Care | 1 | 2018 | 918 | 0.03 | Why? |
| Neoplasm Recurrence, Local | 1 | 2017 | 1063 | 0.02 | Why? |
| Prognosis | 3 | 2018 | 32490 | 0.02 | Why? |
| Program Evaluation | 1 | 2018 | 1929 | 0.02 | Why? |
| Crohn Disease | 1 | 2018 | 959 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2017 | 2886 | 0.02 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.02 | Why? |
| Case-Control Studies | 2 | 2017 | 17671 | 0.02 | Why? |
| Colitis, Ulcerative | 1 | 2018 | 1037 | 0.02 | Why? |
| Sexual Behavior | 1 | 2017 | 1322 | 0.02 | Why? |
| Bayes Theorem | 1 | 2017 | 3237 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.02 | Why? |
| Ketoconazole | 1 | 1987 | 14 | 0.02 | Why? |
| Reproducibility of Results | 2 | 2017 | 11304 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2018 | 2483 | 0.02 | Why? |
| Photosensitivity Disorders | 1 | 1987 | 14 | 0.02 | Why? |
| Sex Distribution | 1 | 2014 | 2083 | 0.02 | Why? |
| Zinc Sulfate | 2 | 1999 | 35 | 0.02 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.02 | Why? |
| Perception | 1 | 2017 | 2827 | 0.02 | Why? |
| Oxidative Stress | 1 | 2017 | 2050 | 0.02 | Why? |
| Dermatitis, Contact | 1 | 1987 | 98 | 0.02 | Why? |
| Skin | 1 | 2018 | 2096 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.02 | Why? |
| Evolution, Molecular | 1 | 2019 | 3691 | 0.02 | Why? |
| Anti-HIV Agents | 1 | 2017 | 2209 | 0.02 | Why? |
| Age Distribution | 1 | 2014 | 3567 | 0.02 | Why? |
| Burnout, Professional | 1 | 2020 | 2489 | 0.02 | Why? |
| Molecular Dynamics Simulation | 1 | 2017 | 4155 | 0.02 | Why? |
| Psoriasis | 1 | 2018 | 1739 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.02 | Why? |
| Patient Care Team | 1 | 2018 | 3556 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Disabled Persons | 1 | 2014 | 1152 | 0.02 | Why? |
| Risk Assessment | 2 | 2018 | 25439 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2017 | 22971 | 0.02 | Why? |
| Smoking | 1 | 2017 | 3358 | 0.02 | Why? |
| Drug Eruptions | 1 | 1987 | 319 | 0.01 | Why? |
| Referral and Consultation | 1 | 2018 | 4816 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 1997 | 6740 | 0.01 | Why? |
| Registries | 1 | 2021 | 12327 | 0.01 | Why? |
| Mass Screening | 1 | 2021 | 8005 | 0.01 | Why? |
| Retrospective Studies | 3 | 2017 | 105322 | 0.01 | Why? |
| Organomercury Compounds | 1 | 1999 | 1 | 0.01 | Why? |
| Ethylmercuric Chloride | 1 | 1999 | 1 | 0.01 | Why? |
| Methylmercury Compounds | 1 | 1999 | 24 | 0.01 | Why? |
| Physicians | 1 | 2018 | 4214 | 0.01 | Why? |
| Phylogeny | 1 | 2017 | 13341 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.01 | Why? |
| Sulfhydryl Compounds | 1 | 1999 | 104 | 0.01 | Why? |
| Viral Load | 1 | 2019 | 15850 | 0.01 | Why? |
| Drug Interactions | 2 | 1996 | 1653 | 0.01 | Why? |
| Cysteine | 1 | 1999 | 238 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2018 | 88759 | 0.01 | Why? |
| Glutathione | 1 | 1999 | 280 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2014 | 8495 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Copper Sulfate | 1 | 1993 | 19 | 0.01 | Why? |
| Ion Transport | 1 | 1993 | 43 | 0.01 | Why? |
| Lithium Compounds | 1 | 1993 | 56 | 0.01 | Why? |
| Magnesium Sulfate | 1 | 1993 | 52 | 0.01 | Why? |
| Sulfates | 1 | 1993 | 78 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.01 | Why? |
| Copper | 1 | 1993 | 288 | 0.01 | Why? |
| Drug Evaluation | 1 | 1987 | 100 | 0.01 | Why? |
| Itraconazole | 1 | 1987 | 135 | 0.00 | Why? |
| Child | 1 | 1987 | 70012 | 0.00 | Why? |